## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Peter S. LU, et al.

Group Art Unit: 1648

Filing Date: July 29, 2003

CONFIRMATION NO: 4993

Title: METHODS OF DIAGNOSING CERVICAL CANCER

\_

## FILED ELECTRONICALLY ON: March 8, 2007

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached form PTO/SB/08. A copy of each listed publication is submitted, if required, pursuant to 37 CFR §§1.97-1.98, as indicated below.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached form PTO/SB/08 in accordance with MPEP \$609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

A.	$\boxtimes$ 37 CFR §1.97(b). This Information Disclosure Statement should be considered by the Office because:					
		(1)	It is being filed within 3 months of the filing date of a national application and is other than a continued prosecution application under $\S1.53(d)$ ;			
			OR			
		(2)	It is being filed within 3 months of entry of the national stage as set forth in $\S1.491$ in an international application;			
			OR			
		(3)	It is being filed before the mailing of a first Office action on the merits;			
			- OR			
	⊠	(4)	It is being filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.			
В.	c). Although this Information Disclosure Statement is being filed after the period R §1.97(b), above, it is filed before the mailing date of the earlier of (1) a final §1.113, (2) a notice of allowance under §1.311, or (3) an action that otherwise on the merits, this Information Disclosure Statement should be considered because yone of:					
	Π	a states	ment as specified in §1.97(e) provided concurrently herewith;			
			- OR			
			f \$180.00 as set forth in \$1.17(p) authorized below, enclosed, or included with the nt of other papers filed together with this statement.			
C.	date of the	earlier o	d). Although this Information Disclosure Statement is being filed after the mailing of (1) a final office action under §1.113 or (2) a notice of allowance under §1.311, fore payment of the issue fee and should be considered because it is accompanied			
		i. a st	atement as specified in §1.97(e);			
			AND			
			ee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included hithe payment of other papers filed together with this Statement.			
D.	☐ 37 CF	R §1.97(	e). Statement.			
		A state	ment is provided herewith to satisfy the requirement under 37 CFR §§1.97(c);			
			AND/OR			
		A state	ment is provided herewith to satisfy the requirement under 37 CFR §§1.97(d);			
			AND/OR			
		inform the co	y of a dated communication from a foreign patent office clearly showing that the ation disclosure statement is being submitted within 3 months of the filing date on mmunication is provided in lieu of a statement under 37 C.F.R. § 1.97(c)(1) as of for under MPEP 609.04(b) V.			
E.	disclosure application	statement that wa	ter 37 C.F.R. §1.704(d). Each item of information contained in the information at was first cited in a communication from a foreign patent office in a counterpart is received by an individual designated in § 1.56(c) not more than thirty (30) days of this information disclosure statement. This statement is made pursuant to the			

		ats of 37 C.F.R. §1.704(d) to avoid reduction of the period of adjustment of the patent term ant(s) delay.
F.	37 CF.	R §1.98(a)(2). The content of the Information Disclosure Statement is as follows:
		Copies of each of the references listed on the attached Form PTO/SB/08 are enclosed herewith.
		OR
		Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08 are NOT enclosed.
		AND/OR
	$\boxtimes$	Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Form PTO/SB/08 are enclosed in accordance with 37 CFR §1.98 (a)(2).
		AND/OR
		Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR §1.98(a)(2)(iii).
G.	37 CF references.	R §1.98(a)(3). The Information Disclosure Statement includes non-English patents and/or
		Pursuant to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith.
		Pursuant to MPEP 609(B), an English language copy of a foreign search report is submitted herewith to satisfy the requirement for a concise explanation where non-English language information is cited in the search report.
		- OR
		A concise explanation of the relevance of each patent, publication or other information provided that is not in English is as follows:
		Pursuant to 37 CFR §1.98(a)(3)(ii), a copy of a translation, or a portion thereof, of the non-English language reference(s) is provided herewith.
H.		R §1.98(d). Copies of patents, publications and pending U.S. patent applications, or other a specified in 37 C.F.R. § 1.98(a) are not provided herewith because:
		Pursuant to 37 CFR §1.98(d)(1) the information was previously submitted in an Information Disclosure Statement for another application under which this application claims priority for an earlier effective filing date under 35 U.S.C. 120.
		Application in which the information was submitted:
		Information Disclosure Statement(s) filed on:
		AND
		The information disclosure statement submitted in the earlier application complied with paragraphs (a) through (c) of 37 CFR §1.98.

\( \sumessize \) Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees
of \( \sumessize \) 0.000 and charge any additional fees or credit any overpayment associated with this
communication to Deposit Account No. 23-2415 (Decket No.34170-701,501).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Shirley Chen, Reg. No. 44,608

Dated: March X 2007

650 Page Mill Road Palo Alto, CA 94304-1050 (650) 493-9300 Customer No. 021971

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

				Complete if Known	
Substitute f	or form 1449	PTO		Application Number	10/630,590
INFORM	ATION	DISC	LOSURE	Filing Date	July 29, 2003
			LICANT	First Named Inventor	Peter S. Lu
(Use as many sheets as necessary)				Art Unit	1648
				Examiner Name	Zachariah Lucas
Sheet	1	Of	2	Attorney Docket Number	34170-701.501

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite Ng. <sup>1</sup>	Foreign Patent Document County Code <sup>2</sup> - Number <sup>6</sup> - Kind Code <sup>2</sup> (§ Zumus)	Publication Date MM-DD-YYYY	Name of Patentine or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Pignres Appear	To	
	1.	EP 0523391	01/20/1993	Martin			

Examiner	Date	

The property of the property o

des can be une flaght hosping Trainment is marked

Active and the control of the

PTO/SB/08 (07/05) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

				Complete if Known	
Substitute fo	or form 144	9/PTO		Application Number	10/630,590
INFORM	IATION	DISC	LOSURE	Filing Date	July 29, 2003
STATEM	MENT BY	APP	LICANT	First Named Inventor	Peter S. Lu
(Use as	many shee	ts as nec	cessary)	Art Unit	1648
				Examiner Name	Zachariah Lucas
Sheet	2	Of	2	Attorney Docket Number	34170-701.501

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*					
	2.	PARK, et al. HPV-16-related proteins as the serologic markers in cervical neoplasia. Gynecol Oncol. 1998; 69(1):47-55.			
	3.	ROSALES, et al. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: Correlation with presence of papillomavirus DNA. J. Medical Virology. 2001; 65:736-744.			

Examiner	Date	

Signature | Considered | Consid

code and the Prilighthapper Decidence measured and 1.81. The platements in empired as since or made is betted by the policy balls in the leaf by the USE DETO in present policy and Collection of the Collection of the USE DETO in present policy and Collection of the USE DETO in 1800 and 1800